CPHI Stock Analysis: Buy, Sell, or Hold?
CPHI - China Pharma Holdings, Inc.
$1.05
-0.08 (-7.08%)
▼
5d:
-17.97%
30d:
-13.22%
90d:
-39.31%
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 11, 2026
8d
Get Alerted When CPHI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CPHI is down 18.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CPHI is down 18.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CPHI is currently trading at $1.05, which is considered oversold relative to its 30-day fair value range of $1.19 to $1.32.
Technical Outlook: Technically, CPHI is in a strong downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+165.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CPHI is in a strong downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+165.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.19 -
$1.32
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 165.5% below Wall St target ($3.00)
- WARNING: Recommendation downgraded due to -18.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.19 -
$1.32
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.43
Current Trend
Strong Downtrend
Fundamental Context
Wall Street Target
$3.00
(+165.5%)
Revenue Growth (YoY)
10.9%
Profit Margin
-83.2%
Last updated: February 02, 2026 10:43 AM ET
Data refreshes hourly during market hours. Next update: 11:43 AM
Data refreshes hourly during market hours. Next update: 11:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPHI showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
